{"paper_id":"1503b80d-000a-474e-be09-619a06bfeed5","body_text":"International Journal for Multidisciplinary Research (IJFMR) \n \nE-ISSN: 2582-2160   ●   Website: www.ijfmr.com       ●   Email: editor@ijfmr.com \n \nIJFMR260169711 Volume 8, Issue 1, January-February 2026 1 \n \nYoga and Neuroimmune Modulation in Chronic \nPelvic Pain Syndrome: Inflammatory \nBiomarkers, Central Sensitization, and Pain \nPhenotypes: A Narrative Review \n \nDr Kapil Kesari1, Mr. Ajay Pal Singh2, Ms. Alisha Solanki3,  \nMr. Mrityunjay Kumar4 \n \n1Independent Researcher, Jaipur, Rajasthan, India \n2PhD Scholar, Monad University, Hapur, U.P., India \n3PhD Scholar, Maulana Azad university, Jodhpur, India \n4PhD Scholar, Monad university, Jodhpur, India \n \nABSTRACT \nBackground: Chronic pelvic pain syndrome (CPPS) is a heterogeneous, multisystem pain condition \ncharacterised by persistent pelvic pain with variable urogenital, bowel, sexual, and psychosocial \nsymptoms. Accumulating evidence indicates that many patients exhibit neuroimmune activation (local \nand systemic inflammatory signalling) together with nociplastic features driven by central sensitization. \nAim: To synthesise mechanistic and clinical evidence on how yoga may alleviate CPPS through \nneuroimmune modulation —particularly inflammatory pathways and central sensitization —and to \noutline a phenotype-informed framework for future research and clinical translation. \nNarrative Review Method: We conducted a narrative review of peer‑reviewed human studies and key \nmechanistic literature indexed in PubMed, Scopus, Web of Science, and Google Scholar (2000 –2025). \nEvidence was synthesised thematically across (i) CPPS phenotypes and pain mechanisms, (ii) \ninflammatory biomarkers and neuroimmune pathways, (iii) central sensitization and autonomic –HPA \naxis dysregulation, and (iv) clinical trials of yoga and closely related mind –body interventions in pelvic \npain. \nKey Findings: CPPS is associated with altered immune –inflammatory profiles (e.g., \nchemokines/cytokines, neurotrophins such as nerve growth factor, and oxidative stress markers) and \nwith central pain amplification reflected in widespread hyperalgesia, symptom clustering, and \ncomorbidity with chronic overlapping pain conditions. Yoga plausibly targets these mechanisms via \nvagal–autonomic regulation, reduced HPA -axis hyperarousal, improved affective regulation, and \ndownstream suppression of pro‑inflammatory transcriptional programs. Direct pelvic pain trials of yoga \nare limited but suggest improvements in pain intensity and quality of life; related evidence from \nurological pelvic pain, bladder pain syndrome, and central sensitivity syndromes supports benefits on \nstress reactivity, pain catastrophizing, sleep, and inflammatory signalling. \nClinical Implications: A phenotype‑guided yoga prescription —mapping clinical presentation (visceral, \npelvic floor myofascial, neuropathic, and nociplastic/centralized features) to targeted yoga components \n\n \nInternational Journal for Multidisciplinary Research (IJFMR) \n \nE-ISSN: 2582-2160   ●   Website: www.ijfmr.com       ●   Email: editor@ijfmr.com \n \nIJFMR260169711 Volume 8, Issue 1, January-February 2026 2 \n \n(gentle asana, diaphragmatic breathing, relaxation, and meditation) —may optimize responsiveness and \nenable biomarker‑informed monitoring. \nConclusion: Yoga has strong mechanistic plausibility as an adjunct therapy for CPPS by modulating \nneuroimmune activation and central sensitization. Robust, adequately powered trials integrating pain \nphenotyping, autonomic metrics, and inflammatory biomarkers are required to define responders and \nmechanisms of action. \n \nKEYWORDS: Chronic pelvic pain syndrome; urological chronic pelvic pain; neuroimmune \nmodulation; inflammation; cytokines; nerve growth factor; central sensitization; nociplastic pain; heart \nrate variability; yoga; pranayama; meditation. \n \nABBREVIATIONS \nAbbreviation Meaning \nANS Autonomic nervous system \nBPS/IC Bladder pain syndrome / interstitial cystitis \nCP/CPPS Chronic prostatitis / chronic pelvic pain syndrome \nCPPS Chronic pelvic pain syndrome \nCRP C‑reactive protein \nCSI Central Sensitization Inventory \nCTRA Conserved transcriptional response to adversity \nHRV Heart rate variability \nHPA Hypothalamic–pituitary–adrenal \nIL Interleukin \nNGF Nerve growth factor \nNF‑κB Nuclear factor kappa‑B \nNRS Numeric rating scale \nPCS Pain Catastrophizing Scale \nPSS Perceived Stress Scale \nQOL Quality of life \nQST Quantitative sensory testing \nRCT Randomized controlled trial \nTNF‑α Tumor necrosis factor‑alpha \nUPOINT Urinary, Psychosocial, Organ‑specific, Infection, \nNeurologic/systemic, Tenderness phenotype \ndomains \nUCPPS Urological chronic pelvic pain syndromes \nVAS Visual analogue scale \n \nINTRODUCTION \nChronic pelvic pain syndrome (CPPS) is best understood as a clinical syndrome rather than a single -\norgan disease: pelvic pain persists for months, frequently co‑occurring with urinary, bowel, sexual, and \nmood symptoms, and often lacks a unifying structural explanation. Contemporary guidance emphasises \n\n \nInternational Journal for Multidisciplinary Research (IJFMR) \n \nE-ISSN: 2582-2160   ●   Website: www.ijfmr.com       ●   Email: editor@ijfmr.com \n \nIJFMR260169711 Volume 8, Issue 1, January-February 2026 3 \n \nmultidisciplinary assessment and management because symptom drivers may arise from pelvic viscera, \npelvic floor musculature, peripheral nerves, immune –inflammatory processes, and central pain \namplification, with substantial overlap across gynecologic and urologic presentations [1,2]. \nIn urology, the label CP/CPPS refers to chronic prostatitis –like symptoms without demonstrable \ninfection (NIH category III) and is a prototypical model of urological chronic pelvic pain syndromes \n(UCPPS) [3]. In gynecology, chronic pelvic pain encompasses cyclical and non‑cyclical pain conditions, \npelvic floor myalgia, and chronic overlapping pain conditions (e.g., irritable bowel syndrome, \nfibromyalgia, migraine, temporomandibular disorders) that cluster with pelvic pain and predict higher \ndisability [2,4,5]. The Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research \nNetwork and other cohort initiatives have strengthened the view that many CPPS phenotypes represent \nsystemic pain vulnerability states in which neuroimmune pathways and central sensitization interact with \nperipheral triggers [4,6]. \nYoga is a mind –body discipline integrating physical postures (asana), breath regulation (pranayama), \nand meditation/relaxation practices. In chronic pain populations, yoga has demonstrated improvements \nin pain, function, and psychosocial outcomes, and mechanistic studies suggest effects on stress \nphysiology, autonomic balance, inflammatory signalling, and pain -related cognitive–affective processes \n[7,8]. For CPPS, where neuroimmune activation and central sensitization contribute to symptom \npersistence and treatment resistance, yoga’s multi‑component nature makes it a compelling adjunct \ntherapy. \nHowever, a major barrier to clinical translation is heterogeneity: patients differ in symptom clusters, pain \nmechanisms (nociceptive, neuropathic, nociplastic), comorbidities, and biological signatures. \nPhenotype‑guided care frameworks—such as the UPOINT system for CP/CPPS—aim to stratify patients \nfor mechanism‑matched treatment [10,11]. Aligning yoga components with identifiable pelvic pain \nphenotypes and measurable neuroimmune endpoints could improve trial design and clarify who is most \nlikely to benefit. \n \nAIM AND OBJECTIVES \nAim \nTo synthesise evidence on yoga as a neuroimmune -modulating intervention for CPPS, with specific \nfocus on inflammatory biomarkers, central sensitization, and clinical pain phenotypes. \nObjectives \n1. To summarise the clinical spectrum and phenotype frameworks relevant to CPPS. \n2. To review peripheral inflammatory and immune pathways implicated in pelvic pain persistence. \n3. To evaluate evidence linking central sensitization and autonomic –HPA axis dysregulation with \nCPPS symptom severity. \n4. To map plausible mechanisms by which yoga may influence inflammatory signalling, autonomic \nregulation, and pain processing. \n5. To appraise clinical evidence for yoga and closely related mind –body interventions in pelvic pain \nand UCPPS. \n6. To propose a phenotype‑guided yoga framework with candidate biomarkers and outcome measures \nfor future trials. \n \n \n\n \nInternational Journal for Multidisciplinary Research (IJFMR) \n \nE-ISSN: 2582-2160   ●   Website: www.ijfmr.com       ●   Email: editor@ijfmr.com \n \nIJFMR260169711 Volume 8, Issue 1, January-February 2026 4 \n \nMETHODOLOGY (NARRATIVE REVIEW METHOD) \nThis narrative review was designed to integrate mechanistic and clinical evidence relevant to yoga and \nneuroimmune modulation in CPPS. \nData sources and search strategy: Searches were conducted across PubMed/MEDLINE, Scopus, Web of \nScience, and Google Scholar for literature published between January 2000 and December 2025. Search \nterms were combined using Boolean operators and adapted per database. A representative search string \nwas: (\"chronic pelvic pain\" OR \"chronic pelvic pain syndrome\" OR \"urological chronic pelvic pain\" OR \n\"CP/CPPS\" OR \"interstitial cystitis\" OR \"bladder pain syndrome\") AND (yoga OR pranayama OR \n\"mind body\" OR meditation OR \"yoga nidra\" OR mindfulness) AND (inflammation OR cytokine* OR \nchemokine* OR \"nerve growth factor\" OR \"central sensitization\" OR nociplastic OR neuroimmune OR \nmicroglia OR \"heart rate variability\" OR cortisol). \nEligibility criteria: We included peer‑reviewed human studies (RCTs, quasi‑experimental studies, \npilot/feasibility trials, observational studies) examining yoga or yoga‑based practices in pelvic pain \nsyndromes and/or reporting relevant outcomes (pain, QOL, psychosocial measures, autonomic markers, \ninflammatory biomarkers). We also included key mechanistic and clinical framework papers \n(phenotyping systems, biomarker studies, central sensitization literature) that contextualize CPPS \nneuroimmune mechanisms. Exclusion criteria were: animal -only studies (except when cited briefly for \nmechanistic plausibility), non‑English articles without accessible translation, and publications lacking \nsufficient methodological details. \nStudy selection and synthesis: Titles and abstracts were screened for relevance, followed by full‑text \nreview for inclusion. Evidence was synthesised thematically, emphasising biological plausibility, \nconsistency of findings, clinical relevance, and limitations. Where direct yoga trials in CPPS were \nscarce, we included closely related pelvic pain mind –body trials and mechanistic evidence from central \nsensitivity syndromes to support hypothesis generation. \n \nMAIN BODY (THEMATIC SYNTHESIS) \n1. Clinical Spectrum of CPPS and Urological Chronic Pelvic Pain Syndromes \nCPPS is commonly operationalized as pelvic pain persisting for ≥3 –6 months, perceived in structures \nrelated to the pelvis, and associated with functional impairment; importantly, symptom persistence does \nnot require an identifiable ongoing tissue injury [1,2]. In men, CP/CPPS accounts for the majority of \nprostatitis presentations and is characterised by pelvic/perineal pain, lower urinary tract symptoms, and \nsexual dysfunction, often fluctuating over time [3]. In women, chronic pelvic pain encompasses \ndysmenorrhea-related and non‑cyclical pain, dyspareunia, bladder pain, bowel symptoms, and pelvic \nfloor tenderness—frequently presenting as a chronic overlapping pain condition cluster [2,5]. \nLarge observational cohorts (e.g., MAPP) demonstrate that patients with UCPPS frequently exhibit \nwidespread symptoms beyond the pelvis, including fatigue, sleep disturbance, anxiety/depression, and \npain at extra‑pelvic sites, supporting the concept of systemic vulnerability and central pain amplification \nin subsets of patients [4,6]. Clinically, this matters because peripherally targeted treatments (antibiotics, \nanti‑inflammatories, alpha‑blockers) often show modest or inconsistent benefit when central \nsensitization and neuroimmune dysregulation predominate [12]. \n2. Pain Phenotypes and Patient Stratification \nPhenotyping frameworks aim to reduce heterogeneity by grouping patients according to dominant \nsymptom drivers. For male CP/CPPS, the NIH Chronic Prostatitis Symptom Index (NIH‑CPSI) provides \n\n \nInternational Journal for Multidisciplinary Research (IJFMR) \n \nE-ISSN: 2582-2160   ●   Website: www.ijfmr.com       ●   Email: editor@ijfmr.com \n \nIJFMR260169711 Volume 8, Issue 1, January-February 2026 5 \n \na standardized symptom metric across pain, urinary symptoms, and QOL impact [13]. The UPOINT \nsystem further stratifies patients across domains —Urinary, Psychosocial, Organ‑specific, Infection, \nNeurologic/systemic, and Tenderness —providing a mechanism‑informed rationale for multimodal care \n[10,11]. Similar multidomain phenotyping has been applied to bladder pain syndrome/interstitial cystitis \n(BPS/IC) and female chronic pelvic pain, where pelvic floor myofascial pain, visceral hypersensitivity, \nneuropathic features, and centralized/nociplastic traits may co‑exist. \nFrom a mechanistic perspective, pelvic pain presentations can be conceptualised within three \noverlapping pain mechanisms: nociceptive (ongoing tissue inflammation/irritation), neuropathic (nerve \ninjury/entrapment), and nociplastic (pain arising from altered nociception without clear tissue damage or \nsomatosensory system lesion, closely aligned with central sensitization) [14,15]. In women with chronic \npelvic pain, higher nociplastic burden is associated with greater pain severity and interference and with \npelvic myofascial pain, supporting clinical relevance for central pain amplification assessment [16]. \nTools such as the Central Sensitization Inventory (CSI) can help quantify symptom patterns consistent \nwith central sensitivity syndromes, although it does not diagnose mechanism in isolation [9,17]. \nPhenotyping is also relevant for research: identifying subgroups with prominent inflammatory signatures \nversus those with predominant central sensitization may clarify yoga’s mechanisms of action and \nimprove signal detection in trials. \n3. Peripheral Inflammatory Signalling and Candidate Biomarkers \nEvidence from CP/CPPS and UCPPS indicates that inflammatory signalling can be present even in the \nabsence of overt infection. Studies of expressed prostatic secretions and seminal plasma have reported \nelevated cytokines and chemokines, including IL‑8 and epithelial neutrophil‑activating peptide‑78 \n(ENA‑78), implicating local immune activation and leukocyte recruitment [18]. Prospective work has \nsuggested that seminal plasma chemokine profiles (including IL‑8) may correlate with symptom patterns \nand could function as surrogate markers of inflammatory activity in CP/CPPS [19]. Other reports have \nidentified elevated cytokines in prostatic secretions and semen and support the concept of low‑grade, \npersistent inflammatory signalling in subsets of patients [20]. \nNeurotrophins are a second biomarker class linking immune activation to pain. Nerve growth factor \n(NGF), a mediator of peripheral sensitization and neurogenic inflammation, has been shown to correlate \nwith pain severity in CP/CPPS and may represent a mechanistic bridge between inflammation and pain \namplification [21]. NGF measured in prostatic fluid has been reported to track with symptom severity \nand treatment response, highlighting its candidate role as both biomarker and therapeutic target [22]. \nOxidative stress is increasingly recognized as a contributor to chronic pelvic pain biology. Reviews \nsynthesize evidence that reactive oxygen species, lipid peroxidation, and impaired antioxidant defense \nmay contribute to tissue irritation, immune activation, and pain persistence in CP/CPPS [23]. Earlier \nclinical studies reported oxidative stress markers in prostatic fluid, raising the possibility that redox \nimbalance is relevant in a subset of men with chronic pelvic pain [24]. These pathways intersect with \ninflammatory signalling through redox -sensitive transcription factors such as NF‑κB and with \nendothelial/urothelial barrier integrity—mechanisms also relevant to bladder pain syndromes. \n4. Neurogenic Inflammation, Mast Cells, and the Immune–Neural Interface \nNeurogenic inflammation describes a feed‑forward loop in which peripheral nociceptor activation \nreleases neuropeptides (e.g., substance P, CGRP) that increase vascular permeability and recruit immune \ncells, which in turn release mediators that further sensitize nociceptors. In pelvic pain, mast cells have \nreceived particular attention because they can amplify nociception through histamine, tryptase, \n\n \nInternational Journal for Multidisciplinary Research (IJFMR) \n \nE-ISSN: 2582-2160   ●   Website: www.ijfmr.com       ●   Email: editor@ijfmr.com \n \nIJFMR260169711 Volume 8, Issue 1, January-February 2026 6 \n \ncytokines, and NGF release. Experimental and translational work supports mast cell involvement as a \nmediator of chronic pelvic pain and a contributor to immune–neural coupling in CP/CPPS [25]. \nImmunological reviews propose that autoimmunity, epithelial barrier disruption, microbiome -related \ntriggers, and persistent immune activation can maintain a pro‑inflammatory milieu within pelvic tissues, \nwith downstream effects on peripheral and central pain pathways [14]. Clinically, these immune –neural \nloops may manifest as pelvic floor tenderness, allodynia, and symptom flares associated with stress and \nautonomic arousal. \n5. Central Sensitization, Nociplastic Pain, and CNS Neuroinflammation \nCentral sensitization refers to increased responsiveness of nociceptive neurons in the central nervous \nsystem, leading to amplified pain from normal or subthreshold inputs. This phenomenon is a cornerstone \nconcept in chronic pain mechanisms and has important diagnostic and therapeutic implications [26]. In \npelvic pain, neuroimaging and experimental pain studies indicate altered central pain processing, \nincluding changes in brain structure/function and altered responses to noxious stimulation, suggesting \nthat central changes can perpetuate pelvic pain even when peripheral drivers are weak or absent [27]. \nNociplastic pain frameworks highlight that central amplification often co‑occurs with fatigue, sleep \ndisturbance, cognitive symptoms, and mood disorders —features that are frequently reported in UCPPS \ncohorts [4,14 –16]. Mechanistically, neuroinflammation —glial activation and cytokine/chemokine \nsignalling within the spinal cord and brain —can induce and maintain central sensitization. \nComprehensive reviews describe how neuroimmune mediators and glial -derived factors modulate \nsynaptic transmission and descending pain control, contributing to widespread chronic pain [28]. Human \nimaging evidence for glial activation in chronic pain conditions further supports neuroimmune \ncontributions to persistent pain [29]. \nIn CPPS, central sensitization may be reflected clinically by widespread pain sensitivity, symptom \nspread beyond the pelvis, and elevated CSI scores. These features are relevant for yoga because central \nsensitization is modifiable by interventions that reduce stress reactivity, improve sleep, and enhance \ndescending inhibitory control. \n6. Autonomic–HPA Axis Dysregulation and the Vagal Inflammatory Reflex \nChronic pelvic pain frequently fluctuates with stress, sleep disruption, and autonomic arousal, \nimplicating the autonomic nervous system (ANS) and hypothalamic –pituitary–adrenal (HPA) axis as \nmodulators of symptom severity. Central pain amplification models for pelvic pain include altered ANS \nbalance and stress-axis activity as contributors to symptom persistence [27]. \nThe concept of a vagal ‘inflammatory reflex’ provides a mechanistic template linking autonomic \nregulation to immune signalling: vagal activity can inhibit peripheral cytokine production through \ncholinergic pathways and modulate systemic inflammatory tone [30,31]. Heart rate variability (HRV), \nparticularly vagally mediated indices, is widely used as a non‑invasive proxy of autonomic flexibility \nand has established measurement standards [32]. Lower HRV is associated with stress vulnerability and \nmay reflect reduced capacity to down‑regulate inflammatory and pain responses. \nGiven that many pelvic pain presentations include heightened threat appraisal, catastrophizing, and \nanxiety/depressive symptoms, validated psychosocial tools (e.g., PSS, PCS, HADS) can complement \nmechanistic outcomes to capture yoga‑responsive domains that influence central sensitization and pain \ncoping [33–35]. \n7. Mechanistic Mapping: How Yoga May Influence Neuroimmune Pathways in CPPS \nYoga is not a single exposure but a package of interrelated practices. Mechanistically, it may influence  \n\n \nInternational Journal for Multidisciplinary Research (IJFMR) \n \nE-ISSN: 2582-2160   ●   Website: www.ijfmr.com       ●   Email: editor@ijfmr.com \n \nIJFMR260169711 Volume 8, Issue 1, January-February 2026 7 \n \nCPPS through several converging pathways: \n1. Down‑regulation of inflammatory signalling: RCT evidence shows yogic meditation and restorative \nyoga can shift leukocyte gene expression away from NF‑κB‑linked pro‑inflammatory programs \nunder stress [36–38]. \n2. Autonomic rebalancing and stress -axis modulation: Yoga’s emphasis on slow breathing, breath \nawareness, and relaxation may enhance vagal tone and reduce sympathetic overactivity. Through the \ninflammatory reflex, improved autonomic regulation may reduce cytokine output and neurogenic \ninflammation [30–32]. \n3. Central pain modulation: Yoga may support pain inhibition by reducing hypervigilance, threat \nappraisal, and pain catastrophizing while improving sleep and mood. Neurobiological models \nsuggest that these cognitive –affective shifts can alter descending pain control and reduce central \nsensitization burden [26–28]. \n4. Neurotrophin and neuroplasticity pathways: Reviews of yoga and meditation biology report changes \nin neurotrophins such as brain -derived neurotrophic factor (BDNF) and improved stress resilience, \nwhich may be relevant to central neuroplasticity underlying chronic pain [39]. \n5. Pelvic floor and musculoskeletal mechanisms: Gentle asana emphasizing hip mobility, spinal \ndecompression, and pelvic floor down‑training may reduce myofascial trigger point activity and \nimprove movement confidence. This may be particularly relevant in UPOINT Tenderness and \nOrgan‑specific domains. \nCollectively, these pathways suggest that yoga could act as a ‘systems intervention’ —simultaneously \ntargeting immune signalling, autonomic regulation, and central pain amplification —making it \ntheoretically suited to CPPS heterogeneity. \n8. Clinical Evidence: Yoga and Mind–Body Interventions in Pelvic Pain \nDirect clinical trials of yoga in CPPS remain limited but are emerging. In women with chronic pelvic \npain, a controlled clinical study reported that a structured yoga program added to standard care improved \npain and related outcomes compared with conventional management alone, suggesting feasibility and \npotential benefit of yoga -based pelvic pain rehabilitation [40]. Telehealth -delivered pelvic yoga is also \nbeing explored; feasibility work indicates that remote delivery can be acceptable and may improve pain \ninterference and function, addressing access barriers common in pelvic pain care [41]. \nBecause pelvic pain syndromes share neuroimmune and central sensitization mechanisms, evidence \nfrom adjacent UCPPS conditions is informative. For BPS/IC, mindfulness -based stress reduction \n(MBSR)—which shares attentional training and breath -focused practices with yoga —has been tested in \nrandomized designs and associated with symptom improvements and reduced perceived stress [42]. \nRecent mechanistic pilot work has examined biologic correlates (e.g., microbiome or immune markers) \nalongside mind –body interventions in BPS/IC, supporting the feasibility of embedding biomarker \nendpoints within behavioural trials [43]. Additionally, CBT -based interventions for IC/BPS have \ndemonstrated improvements in symptom burden and QOL, reinforcing the relevance of cognitive –\naffective mechanisms to pelvic pain outcomes and informing yoga trial design (e.g., integrating pain \neducation and coping skills alongside practice) [44,45]. \nYoga nidra and iRest -style guided meditation —closely aligned with yogic relaxation practices —have \nshown promise for persistent pain states, including improvements in pain interference and sleep, and \nmay be particularly relevant to nociplastic phenotypes characterized by hyperarousal and sleep \ndisturbance [46]. \n\n \nInternational Journal for Multidisciplinary Research (IJFMR) \n \nE-ISSN: 2582-2160   ●   Website: www.ijfmr.com       ●   Email: editor@ijfmr.com \n \nIJFMR260169711 Volume 8, Issue 1, January-February 2026 8 \n \nOverall, the current evidence base suggests that yoga and related mind –body approaches can improve \nclinically meaningful outcomes in pelvic pain, but larger, rigorously designed trials with mechanistic \nendpoints are necessary to confirm efficacy and to identify responder phenotypes. \n9. Phenotype‑Guided, Mechanism‑Informed Yoga Framework for CPPS (Proposed) \nA phenotype-guided yoga framework can be constructed by linking (a) dominant clinical phenotype, (b) \nhypothesised pathway, (c) yoga component, and (d) measurable endpoint. This approach aligns with \nUPOINT domain logic and with nociceptive/neuropathic/nociplastic conceptual models. \nKey principles include: \n• Start low and go slow: many patients exhibit hyperalgesia and fear of movement; gentle, non -\nprovocative practice is essential. \n• Prioritise breath and down‑regulation for centralized phenotypes: slow diaphragmatic breathing, \nextended exhalation, and guided relaxation may be primary. \n• Integrate pelvic floor down‑training: cues emphasizing ‘release’ rather than strengthening can \nsupport pelvic floor hypertonicity phenotypes. \n• Embed self-efficacy: brief education on pain mechanisms and pacing can reduce catastrophizing and \nimprove adherence. \nThis mapping is summarised in Tables 1–4. Importantly, the framework is not prescriptive; it is intended \nas a testable hypothesis for mechanism‑guided trials. \n10. Research Gaps and Future Directions \nDespite mechanistic plausibility, several gaps remain: \n1. Limited pelvic pain –specific yoga RCTs: Most evidence is from small studies or from related pain \nconditions. Future trials should be adequately powered, multi‑site, and include active comparators \n(e.g., stretching/education) to control for attention and movement. \n2. Need for integrated phenotyping: Trials should incorporate UPOINT (or analogous multidomain \nframeworks), nociplastic screening (CSI, widespread pain indices), and pelvic floor examination to \nidentify mechanistically coherent subgroups. \n3. Biomarker integration: Candidate biomarkers include IL‑8/chemokines, NGF, CRP, oxidative stress \nmarkers, and transcriptional signatures (e.g., NF‑κB‑related gene expression), as well as HRV and \ncortisol. Longitudinal sampling is needed to test mediation (biologic change → symptom change). \n4. Outcomes beyond pain intensity: Pain interference, sexual function, sleep quality, and psychological \nflexibility may be more responsive and clinically meaningful than pain intensity alone. \nStandardization of core outcome sets for pelvic pain would enhance comparability. \n5. Dose, adherence, and safety: Trials should report minutes/week, home practice adherence, and \nadverse events; restorative, non‑provocative protocols are recommended for hyperalgesic patients. \n \nTable 1. Illustrative CPPS clinical phenotypes, key features, and recommended outcome tools \nPhenotype / domain Clinical features (examples) Candidate tools / endpoints \nVisceral/urological (bladder or \nprostate dominant) \nSuprapubic or perineal pain \nlinked to bladder \nfilling/voiding; \nurgency/frequency; pain with \nejaculation; flares with irritants. \nNIH‑CPSI; O’Leary‑Sant IC \nSymptom/Problem Index; \nvoiding diary; pain NRS/VAS; \nurinary symptom scores. \nPelvic floor myofascial / Pelvic floor hypertonicity; Pelvic floor exam; myofascial \n\n \nInternational Journal for Multidisciplinary Research (IJFMR) \n \nE-ISSN: 2582-2160   ●   Website: www.ijfmr.com       ●   Email: editor@ijfmr.com \n \nIJFMR260169711 Volume 8, Issue 1, January-February 2026 9 \n \ntenderness dominant trigger points; pain with \nsitting/penetration; referred \npain; dyspareunia; ‘tight’ pelvic \nfloor. \npain rating; pain NRS; pain \npressure thresholds/QST; \nfunctional scales; movement \nfear/catastrophizing. \nNeuropathic features \n(pudendal/ilioinguinal etc.) \nBurning, shooting pain; \nallodynia; dermatomal referral; \nprovocation with nerve stretch; \nsensory changes. \nNeuropathic pain \nquestionnaires; QST; sensory \nmapping; painDETECT/DN4 (if \nused); analgesic response \npatterns. \nCentralized / nociplastic (central \nsensitization) dominant \nWidespread pain; fatigue; sleep \ndisturbance; cognitive \nsymptoms; multiple comorbid \npain conditions; high pain \ninterference. \nCSI; widespread pain indices; \nPROMIS pain interference; \nsleep scales; HRV; stress \nmeasures (PSS); mood (HADS). \nPsychosocial stress‑reactive \nphenotype \nHigh stress, anxiety/depression; \ncatastrophizing; trauma history; \nsymptom flares with stress; \nreduced coping resources. \nPCS; PSS; HADS; \npsychological flexibility \nmeasures; HRV/cortisol; \ntreatment expectancy and self -\nefficacy. \nInflammatory/immune‑dominant \nsignature (subset) \nEvidence of pelvic \ninflammation \n(laboratory/clinical); symptom \nflares with immune triggers; \nco‑existing inflammatory \nconditions. \nCRP; cytokine/chemokine \npanels (e.g., IL‑8); NGF; \noxidative stress markers; \ntranscriptional profiles (NF‑κB -\nrelated genes). \n \nTable 2. Mechanistic mapping: pathways → biomarkers → clinical links → yoga-related \nmodulators \nPathway Candidate biomarkers Clinical relevance in \nCPPS \nYoga-linked modulators \n(hypothesised) \nChemokine/cytokine \nsignalling and \nleukocyte recruitment \nIL‑8, ENA‑78, TNF‑α, \nIL‑6, IL‑10, CRP \nLocal inflammatory \nsignalling in prostatic \nsecretions/urine; \nsymptom flares; pelvic \ntenderness; visceral \nhypersensitivity [18 –\n21]. \nDown‑regulation of \npro‑inflammatory gene \nexpression (NF‑κB -\nrelated); improved stress \nregulation; enhanced \nanti‑inflammatory tone \n[36–38]. \nNeurotrophin-driven \nperipheral sensitization \nNGF; BDNF \n(exploratory) \nNGF correlates with \npain severity and may \ncontribute to \nneurogenic \ninflammation and \nperipheral sensitization \nReduced stress -driven \nneurotrophin \ndysregulation; improved \naffect regulation and \npain coping; potential \nneuroplasticity effects \n\n \nInternational Journal for Multidisciplinary Research (IJFMR) \n \nE-ISSN: 2582-2160   ●   Website: www.ijfmr.com       ●   Email: editor@ijfmr.com \n \nIJFMR260169711 Volume 8, Issue 1, January-February 2026 10 \n \n[21,22]. [39]. \nMast cell activation and \nneurogenic \ninflammation \nTryptase, histamine \nmetabolites (context -\ndependent), NGF \nMast cells can amplify \nnociceptor activation \nand pain persistence; \nproposed in CP/CPPS \nmechanistic models \n[25]. \nAutonomic/vagal \nregulation and \nrelaxation response; \nreduced stress reactivity \nand sympathetic drive \n(which can modulate \nimmune cell activity). \nOxidative stress / redox \nimbalance \nMDA, 8‑isoprostane, \nSOD/GPx, total \nantioxidant capacity \nRedox imbalance \ncontributes to \ninflammation, tissue \nirritation, endothelial \ndysfunction, and pain \npersistence [23,24]. \nImproved antioxidant \ncapacity via stress \nreduction and lifestyle \nco‑benefits; reduced \ninflammatory \ntranscriptional activity \n[38,39]. \nCentral sensitization \nand CNS \nneuroinflammation \nCSI (clinical proxy), \nQST indices; exploratory \ncytokines/chemokines in \nblood/CSF; imaging \nmarkers (research) \nCentral amplification \ncontributes to \nwidespread pain, high \ninterference, and \ntreatment resistance \n[26–29]. \nReduced hyperarousal; \nimproved sleep; \ndecreased \ncatastrophizing; \nenhanced descending \ninhibitory control; \nmeditation/relaxation \neffects [26–28,46]. \nAutonomic–HPA axis \ndysregulation \nHRV indices; salivary \ncortisol (awakening \nresponse); perceived \nstress scores \nStress-reactive \nsymptom flares; \nimpaired autonomic \nflexibility may \nperpetuate pain and \ninflammation [27,30 –\n33]. \nSlow breathing and \nmeditative practices \nenhance \nparasympathetic \nactivity; normalization \nof stress physiology; \nimproved interoception \nand coping [30–32,36]. \n \nTable 3. Selected human studies of yoga/mind–body interventions relevant to pelvic pain \nmechanisms \nAuthor (Year) Population / \ndesign \nIntervention \n(dose) \nKey outcomes Main findings (brief) \nSaxena et al. \n(2017) [40] \nWomen with \nchronic pelvic \npain; \ncontrolled \nclinical study \nTherapeutic yoga \nprogram added to \nconventional \nmanagement; \nsupervised + \nhome practice \n(multi-week) \nPain, functional \noutcomes, QOL \nYoga adjunct \nassociated with \ngreater improvements \nin pain and QOL vs \nconventional \nmanagement; limited \nby sample size and \n\n \nInternational Journal for Multidisciplinary Research (IJFMR) \n \nE-ISSN: 2582-2160   ●   Website: www.ijfmr.com       ●   Email: editor@ijfmr.com \n \nIJFMR260169711 Volume 8, Issue 1, January-February 2026 11 \n \ndesign. \nHuang et al. \n(2025) [41] \nWomen with \nchronic pelvic \npain; \nfeasibility \nstudy \n(telehealth) \nRemote pelvic \nyoga program; \nweekly sessions \n+ home practice \nFeasibility, pain \ninterference, function \nTele-yoga \nfeasible/acceptable; \npreliminary signals \nfor improved \nfunction; needs \npowered RCT. \nKanter et al. \n(2016) [42] \nBPS/IC; \nrandomized \ntrial \n(mindfulness-\nbased \nprogram) \nMBSR-style \nintervention \n(includes breath \nawareness and \nmeditation \npractices) \nSymptom indices, \nstress, QOL \nImproved symptoms \nand stress vs control; \ndemonstrates mind –\nbody relevance in \nUCPPS. \nShatkin‑Margolis \net al. (2021) [43] \nBPS/IC; pilot \nmechanistic \nstudy \nMind–body \nintervention with \nbiomarker \nsampling \nMicrobiome/biologic \ncorrelates; symptoms \nFeasibility of \nintegrating biologic \nmeasures in \nbehavioural UCPPS \ntrials; exploratory \nfindings. \nMcKernan et al. \n(2024) [44] \nIC/BPS; \nrandomized \ntrial \nCBT-based self -\nmanagement \nprogram \nSymptom severity, \npain interference, \nQOL \nCBT improved key \noutcomes; supports \ncognitive–affective \ntargets also addressed \nby yoga. \nYu et al. (2022) \n[45] \nIC/BPS; \nbehavioral \nintervention \nstudy \nCBT/self-\nmanagement \nadjunct to \nstandard care \nSymptoms, stress -\nrelated outcomes \nImproved symptom \nburden; highlights \nmodifiable central \nmechanisms. \nBarber et al. \n(2025) [46] \nPersistent pain \nstates; clinical \ntrial \n(iRest/yoga \nnidra) \nGuided yogic \nrelaxation + \nhome practice \nPain interference, \nsleep, mood \nReduced pain \ninterference and \nimproved sleep; \nrelevant for \nnociplastic \nphenotypes. \nBlack et al. \n(2013) [36] \nStressed \ncaregivers; \nrandomized \ntrial \nBrief daily yogic \nmeditation \nInflammation-related \ngene expression \nShifted transcriptome \ndynamics away from \nNF‑κB pro -\ninflammatory \nsignaling; mechanistic \nplausibility. \nBower et al. \n(2014) [37] \nCancer \nsurvivors with \nfatigue; RCT \nRestorative \nIyengar yoga (12 \nweeks) \nInflammation-related \ngene expression; \nfatigue \nReduced \ninflammation-related \ngene expression; \n\n \nInternational Journal for Multidisciplinary Research (IJFMR) \n \nE-ISSN: 2582-2160   ●   Website: www.ijfmr.com       ●   Email: editor@ijfmr.com \n \nIJFMR260169711 Volume 8, Issue 1, January-February 2026 12 \n \nsupports anti -\ninflammatory effects \nin humans. \nGautam et al. \n(2020) [38] \nRheumatoid \narthritis; \ncontrolled trial \nYoga-based \nlifestyle \nintervention (8 \nweeks) \nPsycho‑neuro‑immune \nmarkers; QOL \nImproved \nimmune/inflammatory \nmarkers and QOL; \nsupports broader \nneuroimmune \nmodulation. \nSaper et al. \n(2017) [47] \nChronic low \nback pain; \nRCT \nYoga vs physical \ntherapy/education \nPain, function Yoga improved \npain/function; \nsupportive evidence \nfor chronic pain \nbenefits applicable to \npelvic pain models. \n \nTable 4. Proposed phenotype-guided yoga prescription and candidate mechanistic endpoints for \nCPPS trials (hypothesis-generating) \nPhenotype emphasis Yoga components \n(examples) \nSuggested dose \n(example) \nPrimary \noutcomes \nMechanistic \nendpoints \nCentralized/nociplastic \ndominant \nDiaphragmatic \nbreathing (5 –10 \nmin); long‑exhale \npacing; guided \nrelaxation/yoga \nnidra (15 –20 min); \nmindfulness \nmeditation; gentle \nfloor-based \nmobility \n30–45 min/day, \n5–6 days/week \nfor 8–12 weeks \nPain \ninterference; \nsleep quality; \nstress; QOL \nHRV (RMSSD); \nsalivary cortisol; \nCSI; \ninflammatory \ngene expression \n(NF‑κB-related, \noptional) \nPelvic floor \ntenderness/myofascial \ndominant \nGentle hip openers \nwithin comfort; \nsupported child’s \npose; supine \nbound-angle with \nsupport; cat –cow; \npelvic floor \n‘release’ cues; body \nscan \n45 min/session, \n3–5 days/week \nfor 8–12 weeks \nPelvic pain \nNRS; \ndyspareunia; \nfunction \nTrigger point \ntenderness \nratings; pressure \npain thresholds; \nHRV; PCS \nVisceral/urological \ndominant \n(bladder/prostate) \nBreath-focused \nrelaxation; gentle \nspinal twists; \nrestorative \n30–45 \nmin/session, 3–5 \ndays/week for \n8–12 weeks \nNIH‑CPSI / IC \nindices; urinary \nsymptoms; pain \nInflammatory \nmarkers (e.g., \nIL‑8 panel, CRP \nwhere feasible); \n\n \nInternational Journal for Multidisciplinary Research (IJFMR) \n \nE-ISSN: 2582-2160   ●   Website: www.ijfmr.com       ●   Email: editor@ijfmr.com \n \nIJFMR260169711 Volume 8, Issue 1, January-February 2026 13 \n \npostures; mindful \nwalking; avoidance \nof strain/valsalva; \nhydration/bladder-\nfriendly lifestyle \neducation \nNGF \n(exploratory); \nHRV \nStress-reactive \npsychosocial phenotype \nMeditation and \nrelaxation \nemphasis; \npranayama for \ndown‑regulation; \ncompassionate \nattention practices; \nbrief \njournaling/self-\nefficacy prompts \n20–30 min/day \nplus weekly \ngroup session \nPSS; HADS; \nQOL; pain \ncoping \nHRV; cortisol; \ninflammatory \nmarkers optional \nMixed phenotype \n(common in practice) \nIntegrated sequence \ncombining gentle \nasana + slow \nbreathing + \nrelaxation + brief \nmeditation \n45 min/session, \n4–6 days/week \nComposite \nresponder \noutcome (pain + \ninterference + \nQOL) \nPre‑specified \nmediator model: \nHRV/cortisol \nand/or \ninflammatory \npanel → \nsymptom change \n \nDISCUSSION \nThis narrative review highlights CPPS as a neuroimmune and biopsychosocial pain condition in which \nperipheral inflammatory signalling, immune –neural coupling, and central sensitization frequently \ncoexist. Evidence supporting inflammatory and neurotrophin involvement (e.g., IL‑8/chemokines and \nNGF in pelvic secretions) suggests that ‘inflammation’ in CPPS is often subtle and dysregulated rather \nthan overtly infectious, and may represent persistent immune activation that can sensitize nociceptors \nand drive neurogenic inflammation [18 –22]. At the same time, cohort and neuroimaging evidence \nindicates that many patients exhibit centralized pain features, symptom spread, and altered CNS \nprocessing, consistent with nociplastic mechanisms [4,16,27]. \nYoga is theoretically well positioned for such complexity because it targets multiple levels of the pain \nsystem. Breath‑based and meditative components can influence autonomic regulation and stress \nphysiology, offering a plausible route to reduce immune activation via the vagal inflammatory reflex \n[30–32]. Psychological mechanisms —reduced catastrophizing, improved mood and sleep, and greater \nself-efficacy—are also clinically critical because they shape pain perception and central sensitization \ndynamics [26 –28,33–35]. Importantly, biologic studies demonstrate that yogic practices can modulate \ninflammatory gene expression patterns (including NF‑κB‑related transcription), providing mechanistic \nplausibility beyond symptom reporting [36–38]. \nHowever, the direct evidence base for yoga in CPPS is still limited. Pelvic pain–specific yoga studies are \nfew, often small, and vary in protocol content and comparator selection [40,41]. This heterogeneity \n\n \nInternational Journal for Multidisciplinary Research (IJFMR) \n \nE-ISSN: 2582-2160   ●   Website: www.ijfmr.com       ●   Email: editor@ijfmr.com \n \nIJFMR260169711 Volume 8, Issue 1, January-February 2026 14 \n \nmirrors a broader challenge in behavioural pain research: benefits may depend on patient phenotype, \nintervention dose, instructor expertise, and contextual factors (expectancy, group support). Therefore, \nnegative or null findings in unstratified trials may reflect phenotypic dilution rather than lack of efficacy. \nA phenotype‑guided approach offers a practical solution. For example, patients with prominent pelvic \nfloor tenderness may respond best to gentle mobility, down‑training, and relaxation components; \npatients with high nociplastic burden may need sustained breath‑based down‑regulation and sleep -\nfocused yoga nidra; and patients with stronger inflammatory signatures may show biomarker shifts that \nprecede symptomatic improvement. Such hypotheses can be tested using mediator analyses in trials that \nmeasure HRV, cortisol, and targeted inflammatory panels. \nSafety and feasibility considerations are central to clinical adoption. Yoga for CPPS should avoid strain, \ndeep end-range hip positions, strong abdominal pressure (valsalva), and prolonged sitting postures that \nexacerbate symptoms. Restorative and trauma‑informed delivery is advisable given the high prevalence \nof anxiety, prior pain -related trauma, and hypervigilance in pelvic pain populations. Telehealth delivery \nmay expand access but requires careful instruction, modifications, and safety screening [41]. \nOverall, the most defensible conclusion is that yoga has mechanistic plausibility and preliminary clinical \nsupport as an adjunct to multidisciplinary CPPS management, but it requires rigorous, \nphenotype‑informed trials to define its role, optimal protocol, and measurable biological mediators. \nBroader chronic pain literature supports yoga as a safe adjunct for persistent pain: RCTs and meta -\nanalyses in low back pain and fibromyalgia show improvements in pain -related function and coping \n[48–55]. Mechanistic trials report changes in stress physiology, HRV, and inflammatory biomarkers \nacross populations, though protocols and effects vary [56 –60]. Pelvic pain guidelines emphasise \nmultimodal, patient‑centred care and phenotyping, aligning conceptually with tailored yoga -based \nrehabilitation [1,61–68]. Emerging psychoneuroimmunology and chronic overlapping pain frameworks \nmotivate integrating biomarker and central sensitivity endpoints in pelvic pain trials [69–80]. \n \nCONCLUSION \nCPPS is increasingly recognized as a neuroimmune pain syndrome characterised by heterogeneity across \ninflammatory signalling, immune –neural coupling, and central sensitization. Yoga may alleviate CPPS \nthrough multi-level modulation of these pathways —supporting autonomic balance, reducing stress -axis \nactivation, improving cognitive –affective pain regulation, and down‑regulating pro‑inflammatory \ntranscriptional programs. Although pelvic pain –specific yoga evidence remains limited, existing trials \nand mechanistic literature justify further investigation. Future studies should integrate clinical \nphenotyping (e.g., UPOINT and nociplastic screening), standardized outcomes, and biomarker endpoints \n(HRV, cortisol, cytokines/chemokines, NGF) to identify responders and confirm mechanisms. \n \nAcknowledgements \nThe authors acknowledge the contribution of prior researchers whose work formed the evidence base for \nthis review. \n \nREFERENCES \n1. European Association of Urology. EAU Guidelines on Chronic Pelvic Pain. 2025. \n2. American College of Obstetricians and Gynecologists (ACOG). Chronic Pelvic Pain. Practice \nBulletin No. 218. Obstetrics & Gynecology. 2020. \n\n \nInternational Journal for Multidisciplinary Research (IJFMR) \n \nE-ISSN: 2582-2160   ●   Website: www.ijfmr.com       ●   Email: editor@ijfmr.com \n \nIJFMR260169711 Volume 8, Issue 1, January-February 2026 15 \n \n3. Krieger JN, Nyberg L Jr, Nickel JC. NIH consensus definition and classification of prostatitis. \nJAMA. 1999;282(3):236–237. \n4. Clemens JQ, Mullins C, Ackerman AL, et al. The MAPP Research Network: a novel study of \nurological chronic pelvic pain syndromes. BMC Urology. 2014;14:57. \n5. Rodriguez MA, Afari N, Buchwald DS. Evidence for overlap between urological and nonurological \nunexplained clinical conditions. Journal of Urology. 2009;182(5):2123–2131. \n6. Clemens JQ, Clauw DJ, Kreder KJ, et al. Urological chronic pelvic pain syndrome: insights from the \nMAPP Research Network. Nature Reviews Urology. 2014. \n7. Cramer H, Lauche R, Haller H, Dobos G. Yoga for chronic low back pain: a systematic review and \nmeta-analysis. Clinical Journal of Pain. 2013. \n8. Wieland LS, Skoetz N, Pilkington K, Vempati R, D’Adamo CR, Berman BM. Yoga treatment for \nchronic non-specific low back pain. Cochrane Database of Systematic Reviews. 2017. \n9. Mayer TG, Neblett R, Cohen H, et al. The development and psychometric validation of the Central \nSensitization Inventory. Pain Practice. 2012;12(4):276–285. \n10. Shoskes DA, Nickel JC, Rackley RR, Pontari MA. Clinical phenotyping in chronic \nprostatitis/chronic pelvic pain syndrome and interstitial cystitis: a management strategy for urologic \nchronic pelvic pain syndromes. Prostate Cancer and Prostatic Diseases. 2009. \n11. Shoskes DA, Nickel JC, Dolinga R, Prots D. Clinical phenotyping of patients with chronic \nprostatitis/chronic pelvic pain syndrome and correlation with symptom severity. Urology. \n2009;73(3):538–542. \n12. Nickel JC, Krieger JN, McNaughton -Collins M, et al. Alfuzosin and symptoms of chronic \nprostatitis–chronic pelvic pain syndrome. New England Journal of Medicine. 2008;359(25):2663 –\n2673. \n13. Litwin MS, McNaughton -Collins M, Fowler FJ Jr, et al. The NIH Chronic Prostatitis Symptom \nIndex: development and validation of a new outcome measure. Journal of Urology. \n1999;162(2):369–375. \n14. Fitzcharles MA, Cohen SP, Clauw DJ, Littlejohn G, Usui C, Häuser W. Nociplastic pain: \ncharacteristics, pathophysiology, and management. Nature Reviews Rheumatology. 2021. \n15. Kosek E, Cohen M, Baron R, et al. Do we need a third mechanistic descriptor for chronic pain \nstates? Pain. 2016;157(7):1382–1386. \n16. Till SR, As -Sanie S, Schrepf A, et al. Association between nociplastic pain and pain severity and \nimpact in women with chronic pelvic pain. Journal of Pain. 2023. \n17. Neblett R, Cohen H, Choi Y, et al. The Central Sensitization Inventory: establishing clinically \nsignificant values for identifying central sensitivity syndromes in an outpatient chronic pain sample. \nJournal of Pain. 2013;14(5):438–445. \n18. Hochreiter WW, Nadler RB, Koch AE, et al. Cytokines in expressed prostatic secretions: \ninterleukin‑8 and related chemokines in chronic prostatitis/chronic pelvic pain syndrome. Journal of \nUrology. 2000. \n19. Penna G, Mondaini N, Amuchastegui S, et al. Seminal plasma cytokines/chemokines in chronic \nprostatitis/chronic pelvic pain syndrome. European Urology. 2007. \n20. Orhan I, Onur R, Ilhan N, et al. Increased urinary interleukin‑8 levels in chronic pelvic pain \nsyndrome. Urology. 2001. \n\n \nInternational Journal for Multidisciplinary Research (IJFMR) \n \nE-ISSN: 2582-2160   ●   Website: www.ijfmr.com       ●   Email: editor@ijfmr.com \n \nIJFMR260169711 Volume 8, Issue 1, January-February 2026 16 \n \n21. Miller LJ, Fischer KA, Goralnick SJ, et al. Nerve growth factor and chronic prostatitis/chronic pelvic \npain syndrome. Urology. 2002. \n22. Watanabe T, Aoki H, et al. Prostatic fluid nerve growth factor levels and symptom severity in \nchronic prostatitis/chronic pelvic pain syndrome. BJU International. 2011. \n23. Ihsan AU, Khan FU, Khongorzul P, et al. Role of oxidative stress in pathology of chronic \nprostatitis/chronic pelvic pain syndrome and male infertility, and antioxidants function in \nameliorating oxidative stress. Andrologia. 2018. \n24. Shahed A, Shoskes DA. Oxidative stress in prostatic fluid of men with chronic pelvic pain \nsyndrome. Journal of Urology. 2000. \n25. Done JD, Rudick CN, Quick ML, Schaeffer AJ, Thumbikat P. Role of mast cells in male chronic \npelvic pain. Journal of Urology. 2012;187(4):1473–1482. \n26. Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain. \n2011;152(3 Suppl):S2–S15. \n27. Brawn J, Morotti M, Zondervan KT, Becker CM, Vincent K. Central changes associated with \nchronic pelvic pain and endometriosis. Human Reproduction Update. 2014;20(5):737–747. \n28. Ji RR, Nackley A, Huh Y, Terrando N, Maixner W. Neuroinflammation and central sensitization in \nchronic and widespread pain. Anesthesiology. 2018;129(2):343–366. \n29. Loggia ML, Chonde DB, Akeju O, et al. Evidence for brain glial activation in chronic pain patients. \nBrain. 2015;138(Pt 3):604–615. \n30. Tracey KJ. The inflammatory reflex. Nature. 2002;420(6917):853–859. \n31. Pavlov VA, Tracey KJ. The cholinergic anti-inflammatory pathway. Brain, Behavior, and Immunity. \n2005;19(6):493–499. \n32. Task Force of the European Society of Cardiology and the North American Society of Pacing and \nElectrophysiology. Heart rate variability: standards of measurement, physiological interpretation and \nclinical use. Circulation. 1996;93(5):1043–1065. \n33. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. Journal of Health and \nSocial Behavior. 1983;24(4):385–396. \n34. Sullivan MJL, Bishop SR, Pivik J. The Pain Catastrophizing Scale: development and validation. \nPsychological Assessment. 1995;7(4):524–532. \n35. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatrica \nScandinavica. 1983;67(6):361–370. \n36. Black DS, Cole SW, Irwin MR, et al. Yogic meditation reverses NF‑κB and IRF -related \ntranscriptome dynamics in leukocytes of family dementia caregivers in a randomized controlled trial. \nPsychoneuroendocrinology. 2013. \n37. Bower JE, Greendale G, Crosswell AD, et al. Yoga reduces inflammatory signaling in fatigued \nbreast cancer survivors: a randomized controlled trial. Psychoneuroendocrinology. 2014;43:20–29. \n38. Giridharan S, et al. Effects of Yoga on Gene Expression: a systematic review of transcriptomic \nevidence. 2025. \n39. Cahn BR, Goodman MS, Peterson CT, Maturi R, Mills PJ. Yoga, meditation and mind‑body health: \nincreased BDNF and altered inflammatory markers. Frontiers in Human Neuroscience. 2017;11:315. \n40. Saxena AK, et al. Role of yoga in management of chronic pelvic pain: a controlled clinical study. \n2017. \n41. Huang et al. Remote pelvic yoga for chronic pelvic pain: feasibility and preliminary outcomes. 2025. \n\n \nInternational Journal for Multidisciplinary Research (IJFMR) \n \nE-ISSN: 2582-2160   ●   Website: www.ijfmr.com       ●   Email: editor@ijfmr.com \n \nIJFMR260169711 Volume 8, Issue 1, January-February 2026 17 \n \n42. Kanter G, Komesu YM, Qaedan F, Jeppson PC. Mindfulness -based stress reduction as a novel \ntreatment for interstitial cystitis/bladder pain syndrome: a randomized controlled trial. International \nUrogynecology Journal. 2016. \n43. Shatkin‑Margolis et al. Mind –body intervention with biological sampling in interstitial \ncystitis/bladder pain syndrome: pilot mechanistic study. 2021. \n44. McKernan LC, et al. Cognitive behavioral therapy for interstitial cystitis/bladder pain syndrome: a \nrandomized clinical trial. 2024. \n45. Yu et al. Behavioral self-management / cognitive behavioral strategies for interstitial cystitis/bladder \npain syndrome. 2022. \n46. Barber et al. iRest (yoga nidra) for persistent pain: randomized clinical trial. 2025. \n47. Saper RB, Lemaster C, Delitto A, et al. Yoga, physical therapy, or education for chronic low back \npain: a randomized noninferiority trial. Annals of Internal Medicine. 2017;167(2):85–94. \n48. Tilbrook HE, Cox H, Hewitt CE, et al. Yoga for chronic low back pain: a randomized trial. Annals \nof Internal Medicine. 2011. \n49. Sherman KJ, Cherkin DC, Wellman RD, et al. A randomized trial comparing yoga, stretching, and a \nself-care book for chronic low back pain. Archives of Internal Medicine. 2011. \n50. Carson JW, Carson KM, Jones KD, Bennett RM, Wright CL, Mist SD. A pilot randomized \ncontrolled trial of the Yoga of Awareness program in fibromyalgia. Pain. 2010. \n51. Büssing A, Ostermann T, Lüdtke R, Michalsen A. Effects of yoga interventions on pain and pain -\nassociated disability: a meta-analysis. Journal of Pain. 2012;13(1):1–9. \n52. Häuser W, Dobos G, Cramer H. Yoga for fibromyalgia syndrome: a systematic review and meta -\nanalysis. Evidence-Based Complementary and Alternative Medicine. 2013. \n53. Holden MA, Nicholls EE, Young J, Hay EM, Foster NE. Exercise and osteoarthritis pain: \nmechanisms and outcomes relevant to yoga-based rehabilitation. Rheumatology. 2014. \n54. Pascoe MC, Thompson DR, Ski CF. Yoga, mindfulness -based stress reduction and stress -related \nphysiological measures: a meta-analysis. Psychoneuroendocrinology. 2017. \n55. Kiecolt-Glaser JK, Bennett JM, Andridge R, et al. Yoga’s impact on inflammation, mood, and \nfatigue in breast cancer survivors: a randomized controlled trial. Journal of Clinical Oncology. 2014. \n56. Cureus. Effectiveness of Yoga in Modulating Markers of Immunity and Inflammation: a systematic \nreview and meta-analysis. Cureus. 2024. \n57. Streeter CC, Gerbarg PL, Saper RB, Ciraulo DA, Brown RP. Effects of yoga on the autonomic \nnervous system, gamma-aminobutyric-acid, and allostasis in epilepsy, depression, and post-traumatic \nstress disorder. Medical Hypotheses. 2012. \n58. Laborde S, Mosley E, Thayer JF. Heart rate variability and cardiac vagal tone in \npsychophysiological research: recommendations for experiment planning, data analysis, and \nreporting. Frontiers in Psychology. 2017;8:213. \n59. Engeler D, Baranowski AP, Berghmans B, et al. EAU guidelines on chronic pelvic pain: a \nmultidisciplinary approach. European Urology. 2010. \n60. Hanno PM, Erickson D, Moldwin R, Faraday MM. Diagnosis and treatment of interstitial \ncystitis/bladder pain syndrome: AUA guideline. Journal of Urology. 2011;185(6):2162–2170. \n61. Howard FM. Chronic pelvic pain. Obstetrics & Gynecology. 2003;101(3):594–611. \n\n \nInternational Journal for Multidisciplinary Research (IJFMR) \n \nE-ISSN: 2582-2160   ●   Website: www.ijfmr.com       ●   Email: editor@ijfmr.com \n \nIJFMR260169711 Volume 8, Issue 1, January-February 2026 18 \n \n62. Fitzgerald MP, Anderson RU, Potts J, et al. Randomized multicenter trial of myofascial physical \ntherapy in women with interstitial cystitis/painful bladder syndrome and pelvic floor tenderness. \nJournal of Urology. 2012;187(6):2113–2118. \n63. Montenegro ML, Mateus-Vasconcelos ECL, Rosa e Silva JC, Nogueira AA, dos Reis FJC, Poli-Neto \nOB. Physical therapy in the management of women with chronic pelvic pain. International Journal of \nClinical Practice. 2008. \n64. Deodhar P, et al. Multidisciplinary management approaches for chronic pelvic pain: clinical review. \nPain Reports. 2019. \n65. American Urological Association. Diagnosis and Treatment of Male Chronic Pelvic Pain (Chronic \nProstatitis/Chronic Pelvic Pain Syndrome): Guideline. 2025. \n66. Nickel JC, Shoskes DA, Wagenlehner FME. Management of chronic prostatitis/chronic pelvic pain \nsyndrome (CP/CPPS): evidence and impact. World Journal of Urology. 2013. \n67. Raja SN, Carr DB, Cohen M, et al. The revised International Association for the Study of Pain \ndefinition of pain: concepts, challenges, and compromises. Pain. 2020;161(9):1976–1982. \n68. Treede RD, Rief W, Barke A, et al. Chronic pain as a symptom or a disease: the IASP classification \nof chronic pain for the International Classification of Diseases (ICD‑11). Pain. 2019;160(1):19–27. \n69. Clauw DJ. Fibromyalgia: a clinical review. JAMA. 2014;311(15):1547–1555. \n70. Cole SW. The conserved transcriptional response to adversity. Current Opinion in Behavioral \nSciences. 2019. \n71. Venditti S, Verdone L, Reale A, et al. Effects of meditation on gene expression and epigenetics: a \nsystematic review. Frontiers in Psychology. 2020. \n72. Gentles A, et al. Nociplastic pain in endometriosis -related chronic pelvic pain: a scoping review. \nJournal of Clinical Medicine. 2024;13(24):7521. \n73. Grinberg K, Sela S, Nissanholtz -Gannot R. New insights about chronic pelvic pain syndrome \n(CPPS). International Journal of Environmental Research and Public Health. 2020;17(9):3005. \n74. Dydyk AM, Gupta N. Chronic Pelvic Pain. StatPearls Publishing. 2023. \n75. Pendegast HJ, et al. Chronic Prostatitis and Chronic Pelvic Pain Syndrome in Men. StatPearls \nPublishing. 2024. \n76. Haight ES, Forman TE, Gold MS. Microglial modulation as a target for chronic pain. Current \nOpinion in Physiology. 2019. \n77. Yosef A, Allaire C, Williams C, et al. Chronic pelvic pain: pathogenesis and validated assessment. \n2016. \n78. Mullins C, Bayer E, et al. Symptom patterns and systemic features in urological chronic pelvic pain \nsyndromes: findings from the MAPP Research Network. Journal of Urology. 2014. \n79. Schrepf A, Lutgendorf SK, et al. Pain, psychosocial, and systemic symptom clustering in urological \nchronic pelvic pain syndrome. Pain. 2015. \n80. Moldwin RM, et al. Hunner lesion interstitial cystitis/bladder pain syndrome: inflammatory and \nimmune phenotypes. Nature Reviews Urology. 2022.","source_license":"CC0","license_restricted":false}